| Hu, Wei |
TIGER, NCT04255602: A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients |
|
|
| Recruiting | 4 | 2120 | RoW | Ticagrelor 60mg, Ticagrelor 90mg | Shanghai Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Fudan University | Acute Coronary Syndrome, Coronary Stent Implantation | 12/24 | 12/24 | | |
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. |
|
|
| Recruiting | 3 | 1600 | RoW | rhNRG-1, Neucardin™, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Heart Failure | 02/26 | 02/26 | | |
ASSET-IT, NCT06134622: Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis |
|
|
| Recruiting | 3 | 832 | RoW | Intravenous thrombolysis plus tirofiban, Intravenous thrombolysis plus placebo | The First Affiliated Hospital of University of Science and Technology of China | Acute Ischemic Stroke | 12/26 | 06/27 | | |
NCT05701956: Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion |
|
|
| Recruiting | 3 | 332 | RoW | Tenecteplase, TNK, TNK-tPA, TNKase, rhTNK-tPA, Endovascular thrombectomy, thrombectomy | The First Affiliated Hospital of University of Science and Technology of China | Basilar Artery Occlusion, Acute Cerebrovascular Accident, Stroke Due to Basilar Artery Occlusion | 12/25 | 03/26 | | |
NCT05827042: Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion |
|
|
| Recruiting | 3 | 338 | RoW | Intravenous thrombolysis, Alteplase or Tenecteplase, Endovascular thrombectomy | The First Affiliated Hospital of University of Science and Technology of China | Basilar Artery Occlusion, Acute Cerebrovascular Accident, Stroke Due to Basilar Artery Occlusion | 12/25 | 03/26 | | |
NCT05684172: Intra-arterial TNK Following Endovascular Thrombectomy in Patients With Large Vessel Occlusion of Posterior Circulation |
|
|
| Completed | 2/3 | 208 | RoW | Tenecteplase, endovascular thrombectomy alone | The First Affiliated Hospital of University of Science and Technology of China | Acute Ischemic Stroke, Intracranial Artery Occlusion, Endovascular Thrombectomy | 08/23 | 11/23 | | |
NCT04973735: A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects |
|
|
| Active, not recruiting | 1 | 42 | RoW | LY-CovMab | Luye Pharma Group Ltd., Shandong Boan Biotechnology Co Ltd | Covid19 | 05/21 | 07/21 | | |
NCT05166837: The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects |
|
|
| Completed | 1 | 52 | RoW | STSA-1002 injection, Placebo | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Healthy | 01/23 | 01/23 | | |
NCT05659927: Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects |
|
|
| Active, not recruiting | 1 | 34 | RoW | MG-ZG122 Humanized Monoclonal Antibody Injection, MG-ZG122, Placebo | Shanghai Mabgeek Biotech.Co.Ltd | Asthma | 01/24 | 03/24 | | |
NCT05865574: A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection |
|
|
| Not yet recruiting | 1 | 38 | RoW | BAT1706 Injection, BAT1706 | Bio-Thera Solutions | Healthy Men | 09/23 | 01/24 | | |
NCT05968508: A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects |
|
|
| Active, not recruiting | 1 | 300 | RoW | BAT1806 prefilled subcutaneous injection/RoActemra® (from EU) | Bio-Thera Solutions | Healthy Men | 12/24 | 04/25 | | |
NCT06182384: A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices |
|
|
| Completed | 1 | 46 | RoW | SHR-1314 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Moderate-to-Severe Plaque Psoriasis | 05/24 | 05/24 | | |
NCT06196580: PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval |
|
|
| Completed | 1 | 24 | RoW | repaglinide; midazolam; SHR4640, repaglinide; midazolam; SHR4640; SHR4640 placebo, repaglinide; midazolam; SHR4640 placebo | Jiangsu HengRui Medicine Co., Ltd. | Gout and Hyperuricemia | 02/24 | 02/24 | | |
| Recruiting | 1 | 84 | RoW | HS-10501 tablet, Placebo | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Healthy Subjects | 01/25 | 06/25 | | |
| Completed | 1 | 65 | RoW | HDM1005 injection or placebo | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Obesity and Overweight | 08/24 | 09/24 | | |
NCT06346925: Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects. |
|
|
| Not yet recruiting | 1 | 18 | RoW | Herombopag Olamine Tablets | Jiangsu HengRui Medicine Co., Ltd. | Adult Patients With Chronic Primary ITP, Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy | 07/24 | 07/24 | | |
NCT06171048: Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 236 | RoW | CM310 | Keymed Biosciences Co.Ltd | Healthy | 04/25 | 04/25 | | |
NCT06375031: Comparison of HR011408 and NovoRapid® in Subjects With Diabetics |
|
|
| Recruiting | 1 | 30 | RoW | HR011408 injection; HR011408 injection Placebo, NovoRapid®; HR011408 injection Placebo, HR011408 injection Placebo; HR011408 injection | Jiangsu HengRui Medicine Co., Ltd. | Diabetes | 07/24 | 07/24 | | |
NCT06422039: Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 18 | RoW | HRS-7535（D）Tablets, HRS-7535（C）Tablets | Shandong Suncadia Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 06/24 | 06/24 | | |
NCT06435676: A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects |
|
|
| Recruiting | 1 | 92 | RoW | HRS9531, Placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Overweight or Obesity; Type 2 Diabetes | 09/24 | 09/24 | | |
| Recruiting | 1 | 50 | RoW | HDM1005 injection or placebo, HDM1005 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Overweight and Obesity | 01/25 | 01/25 | | |
| Not yet recruiting | 1 | 60 | RoW | DA-302168S, Placebo of DA-302168S | Chendu DIAO Pharmaceutical Group CO., LTD. | Overweight and Obesity | 06/25 | 09/25 | | |
HDG1901-103, NCT06634927: Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. |
|
|
| Recruiting | 1 | 68 | RoW | Ozempic®, HDG1901 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 11/24 | 02/25 | | |
NCT06654960: Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects |
|
|
| Completed | 1 | 20 | RoW | HRS9531 injection, Metformin Hydrochloride tablets | Fujian Shengdi Pharmaceutical Co., Ltd. | Type 2 Diabetes | 12/24 | 12/24 | | |
NCT06723691: Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects |
|
|
| Active, not recruiting | 1 | 57 | RoW | Acetaminophen, Metformin, Warfarin, Atorvastatin, Digoxin, HRS9531 | Fujian Shengdi Pharmaceutical Co., Ltd. | Type 2 Diabetes | 05/25 | 05/25 | | |
NCT05295329: Effect of Compound Danshen Dripping Pills on Diabetic Patients With Coronary Microcirculation Disturbance |
|
|
| Not yet recruiting | N/A | 120 | RoW | Compound Danshen Dropping Pills, Placebo | Ruijin Hospital | Diabetes | 09/22 | 12/22 | | |
NCT05119647: A Single-Arm Objective Performance Criteria Trial for Intracranial Thrombus Aspiration Catheter |
|
|
| Completed | N/A | 124 | RoW | Thrombus Aspiration Catheter(Ton-bridgeMT) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Acute Ischemic Stroke | 08/22 | 11/22 | | |
| Active, not recruiting | N/A | 60 | RoW | MG-K10 humanized monoclonal antibody injection (prefilled syringe), MG-K10 (prefilled syringe), MG-K10 humanized monoclonal antibody injection（Penicillin bottle）, MG-K10 （Penicillin bottle） | Shanghai Mabgeek Biotech.Co.Ltd, The Second Hospital of Anhui Medical University | Pharmacokinetics | 01/24 | 08/24 | | |
NCT06146790: Evaluation of Endovascular Treatment in Acute Intracranial Distal Medium Vessel Occlusion Stroke |
|
|
| Recruiting | N/A | 564 | RoW | endovascular treatment, Standard medical management | The First Affiliated Hospital of University of Science and Technology of China | Acute Ischemic Stroke, Endovascular Thrombectomy | 12/25 | 03/26 | | |
SOLUTION-2, NCT06374667: The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction |
|
|
| Recruiting | N/A | 134 | RoW | Y-3 ICO injection, Y-3 intravenous injection, Conventional treatment | yilong Wang | Stroke, Acute Ischemic, Blood-Brain Barrier | 03/26 | 03/27 | | |
NCT06559436: Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vessel Occlusions Stroke |
|
|
| Recruiting | N/A | 560 | RoW | Intravenous thrombolysis, Standard medical management | The First Affiliated Hospital of University of Science and Technology of China | Acute Ischemic Stroke | 09/26 | 12/26 | | |
NCT06559475: A Multicenter, Randomized Controlled Clinical Investigation to Evaluate the Safety and Effectiveness of the Super-Bore 8/7F Aspiration Catheters in the Treatment of Acute Intracranial Large Vessel Occlusion |
|
|
| Recruiting | N/A | 360 | RoW | Super-Bore Thrombosis Aspiration Catheter treatment group, Conventional thrombectomy device treatment group | The First Affiliated Hospital of University of Science and Technology of China | Acute Ischemic Stroke, Endovascular Thrombectomy | 12/25 | 04/26 | | |
NCT06794801: Evaluating the Safety and Efficacy of Drug-Coated Autoperfusion Balloons Versus Conventional Drug-Coated Balloons Guided by IVUS-OCT Multimodal Imaging for Treating Acute Myocardial Infarction: OPERA-AMI Study |
|
|
| Not yet recruiting | N/A | 134 | RoW | Drug Coated Autoperfusion Balloon Dilatation Catheter（DCAB）, Conventional Drug coated balloon (DCB), Bingo® PTCA Drug Delivery System | LanZhou University | ST Segment Elevation Myocardial Infarction (STEMI) | 12/26 | 12/30 | | |
BEST-BAO, NCT05631847: Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke |
|
|
| Recruiting | N/A | 336 | RoW | Endovascular treatment, Intravenous thrombolysis (Alteplase) | Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital | Acute Ischemic Stroke, Basilar Artery Occlusion, Thrombosis, Alteplase, Endovascular Treatment | 01/27 | 05/27 | | |
NCT05450757: Shanghai ST-segment Elevation Myocardial Infarction Cohort |
|
|
| Recruiting | N/A | 2000 | RoW | | Ruijin Hospital | ST Elevation Myocardial Infarction | 09/23 | 09/24 | | |
| Zhang, Ye |
NCT05840341: Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer |
|
|
| Recruiting | 3 | 306 | RoW | QingyiHuaji optimized formula, standard chemotherapy | Fudan University | Pancreatic Neoplasms | 12/25 | 12/25 | | |
NCT03915132: Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 47 | RoW | Nimotuzumab, Taixinsheng, VMAT | Chinese Academy of Medical Sciences | Nasopharyngeal Carcinoma | 05/20 | 05/22 | | |
NCT05202275: The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs |
|
|
| Recruiting | 2 | 43 | RoW | Olanzapine, Palonosetron, Aprepitant | Chinese Academy of Medical Sciences | Nausea, Vomiting, Head and Neck Squamous Cell Carcinoma, Radiotherapy Side Effect | 12/22 | 09/23 | | |
| Enrolling by invitation | N/A | 51 | RoW | Hypofractionated Radiation Therapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE, Hypofractionation | 12/26 | 12/26 | | |
NCT05375721: Prevention of PONV With Traditional Chinese Medicine |
|
|
| Recruiting | N/A | 300 | RoW | ST36 acupoint injection | The Second Hospital of Anhui Medical University, The First Affiliated Hospital with Nanjing Medical University, Huashan Hospital, Henan Provincial People's Hospital, The Affiliated Hospital of Xuzhou Medical University, First Affiliated Hospital of Jinan University, Beijing Chao Yang Hospital | Postoperative Nausea and Vomiting | 02/24 | 05/24 | | |
NCT06469034: Mixed Reality and Head-mounted Display for Central Venous Catheterization |
|
|
| Recruiting | N/A | 124 | RoW | conventional ultrasound, Mixed reality and head-mounted display ultrasound | The Second Hospital of Anhui Medical University | Central Venous Catheterization | 06/25 | 06/25 | | |
NCT05060068: Effect of Intravenous S-ketamine on Opioid Consumption |
|
|
| Completed | N/A | 345 | RoW | S-ketamine (low dose), LKET, Placebo, CON, S-ketamine (high dose), HKET | The Second Hospital of Anhui Medical University | Breast Cancer Surgery | 07/24 | 07/24 | | |
NCT05607225: Deep Learning-based Classification and Prediction of Radiation Dermatitis in Head and Neck Patients |
|
|
| Recruiting | N/A | 300 | RoW | | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Radiation Dermatitis, Head and Neck Cancer | 06/25 | 06/25 | | |
| Wei, Hu |
NCT06361355: Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers |
|
|
| Completed | 1 | 128 | RoW | Post-change CMAB807, Prolia | Taizhou Mabtech Pharmaceutical Co.,Ltd | Healthy Volunteers | 06/24 | 07/24 | | |
NCT06159101: A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects |
|
|
| Recruiting | 1 | 304 | RoW | HLX13, CN-sourced ipilimumab, EU-sourced ipilimumab group, US-sourced ipilimumab group | Shanghai Henlius Biotech | Healthy Male Volunteers | 05/24 | 05/24 | | |
NCT05734482: Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers |
|
|
| Completed | 1 | 130 | RoW | Secukinumab | Taizhou Mabtech Pharmaceutical Co.,Ltd | Psoriasis | 07/23 | 07/23 | | |
NCT05808673: Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers |
|
|
| Withdrawn | 1 | 252 | RoW | Post-change CMAB807X, Pre-change CMAB807X, Xgeva® | Taizhou Mabtech Pharmaceutical Co.,Ltd | Healthy Volunteers | 06/24 | 07/24 | | |
| Yang, Yan |
NCT05058040: A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971) |
|
|
| Active, not recruiting | 4 | 2500 | RoW | Sodium Oligomannate Capsules | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 04/25 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight |
|
|
| Recruiting | 3 | 600 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | OSA, Overweight or Obesity | 11/26 | 01/27 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Active, not recruiting | 3 | 878 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 06/26 | 07/28 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT05192798: Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC |
|
|
| Recruiting | 2 | 128 | RoW | Albumin-Bound Paclitaxel, Apatinib Mesylate, Bevacizumab | First Affiliated Hospital Bengbu Medical College | Triple-negative Breast Cancer | 01/25 | 06/25 | | |
NCT04970121: Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy |
|
|
| Recruiting | 2 | 100 | RoW | Duloxetine, Chemotherapy containing taxanes | Yan Yang, MD, Ph.D | Chemotherapy-induced Peripheral Neuropathy, Pain, Solid Tumor | 07/25 | 12/25 | | |
NCT06555471: A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Sintilimab, S-1, Capecitabine, Extraperitoneal radiation therapy | The First Affiliated Hospital with Nanjing Medical University | Gastric Cancer | 12/26 | 12/27 | | |
NCT05693142: AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) |
|
|
| Recruiting | 1/2 | 15 | US | RGX-202 | REGENXBIO Inc. | Duchenne Muscular Dystrophy | 12/25 | 12/25 | | |
NCT04486859: Postoperative Thrombosis Prevention in Patients With CD |
|
|
| Recruiting | N/A | 206 | RoW | LMWH/Rivaroxaban, IPC | Huashan Hospital, Peking Union Medical College Hospital, West China Hospital | Cushing Disease, DVT, Pulmonary Embolism | 02/25 | 05/25 | | |
NCT06506630: Effects of Coenzyme Q10 Supplement on Cardiovascular Risk Factors in Subjects at High Risk of Metabolic Syndrome |
|
|
| Recruiting | N/A | 150 | RoW | coenzyme Q10, placebo | Tian Zezhong | Metabolic Syndrome, Cardiovascular Diseases | 12/24 | 12/24 | | |
| Zhao, Hui |
NCT06368882: Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT） |
|
|
| Recruiting | 4 | 1500 | RoW | Peg-Interferon α, nucleo(s)tide analogue | First Affiliated Hospital of Wenzhou Medical University | Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b | 12/28 | 12/28 | | |
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 738 | RoW | TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive Small Cell Lung Cancer | 12/22 | 12/22 | | |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study |
|
|
| Completed | 3 | 163 | RoW | Lotilaner, TP-03, S-Misoxam, Vehicle Control | LianBio LLC | Blepharitis | 09/23 | 04/24 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
| Recruiting | 2 | 54 | RoW | KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 05/27 | 12/27 | | |
NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR |
|
|
| Recruiting | 1/2 | 160 | RoW | YK-029A | Suzhou Puhe Pharmaceutical Technology Co., LTD | Treatment, Treatment Side Effects | 12/23 | 05/24 | | |
NCT04973735: A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects |
|
|
| Active, not recruiting | 1 | 42 | RoW | LY-CovMab | Luye Pharma Group Ltd., Shandong Boan Biotechnology Co Ltd | Covid19 | 05/21 | 07/21 | | |
NCT03814447: The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer |
|
|
| Recruiting | 1 | 10 | RoW | anti- MESO CAR-T cells, Fludarabine, FA, Cyclophosphamide, CTX | Shanghai 6th People's Hospital, Hrain Biotechnology Co., Ltd. | Ovarian Cancer | 01/23 | 01/23 | | |
NCT05659927: Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects |
|
|
| Active, not recruiting | 1 | 34 | RoW | MG-ZG122 Humanized Monoclonal Antibody Injection, MG-ZG122, Placebo | Shanghai Mabgeek Biotech.Co.Ltd | Asthma | 01/24 | 03/24 | | |
NCT02929290: Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC |
|
|
| Recruiting | 1 | 80 | RoW | BPI-9016M, No other name so far | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 11/24 | 11/24 | | |
NCT05895565: A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects |
|
|
| Recruiting | 1 | 28 | RoW | PMG1015, PMG1015 placebo | Pulmongene Ltd. | IPF | 12/24 | 05/25 | | |
NCT04948502: SaExten Vena Cava Filter System in Prevention of Pulmonary Embolism |
|
|
| Completed | N/A | 192 | RoW | SaExten vena cava filter system, SaExten VCF system, Denali inferior vena cava filter, Denali IVCF | ShenZhen KYD Biomedical Technology Co., Ltd. | Pulmonary Embolism | 01/22 | 09/22 | | |
NCT04568291: CTC in Lung Caner Patients With Bone Metastases |
|
|
| Recruiting | N/A | 160 | RoW | model treatment, routine treatment | Shanghai 6th People's Hospital | Lung Cancer, Bone Metastases, Single Cell Sequencing Technology | 03/22 | 12/22 | | |
NCT03876392: Detection of Bone Marrow Metastases With Magnetic Resonance Imaging |
|
|
| Recruiting | N/A | 50 | RoW | magnetic resonance imaging | Shanghai 6th People's Hospital | Bone Marrow Metastases, Magnetic Resonance Imaging | 12/22 | 12/22 | | |
PROSTA, NCT05356767: The Study of Percutaneous Mechanical Thrombectomy Treating Acute Deep Vein Thrombosis of Lower Extremities |
|
|
| Recruiting | N/A | 600 | RoW | Pharmacomechanical thrombolysis | Chengdu University of Traditional Chinese Medicine | Pharmacomechanical Thrombolysis, Deep Vein Thrombosis | 04/24 | 04/26 | | |
SURF, NCT06539689: A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries |
|
|
| Recruiting | N/A | 240 | RoW | Sperstent® peripheral spot stent system, Everflex® self-expanding peripheral stent system | FrontAce Scientific Co., Ltd | Peripheral Arterial Disease, Stenosis, Dissection | 12/26 | 12/26 | | |
NCT06775808: Total Infectome Characterization of Eye Infections |
|
|
| Recruiting | N/A | 200 | RoW | | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Eye Infections, Diagnosis | 10/26 | 12/26 | | |
NCT05707520: Long-term Benefit of MPA in Liver Transplantation |
|
|
| Recruiting | N/A | 500 | RoW | enteric-coated mycophenolate (MPAs), None MPA | Third Affiliated Hospital, Sun Yat-Sen University, Shulan (Hangzhou) Hospital, RenJi Hospital, The First Affiliated Hospital of Zhengzhou University, Beijing YouAn Hospital, Huashan Hospital, The Third Xiangya Hospital of Central South University, West China Hospital, Hebei Medical University Third Hospital, People's Hospital of Guangxi, Beijing Friendship Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Liver Transplant Rejection, Immunosuppressant Adverse Reaction | 06/23 | 09/23 | | |
| Du, Yi |
| Not yet recruiting | 1 | 60 | RoW | DA-302168S, Placebo of DA-302168S | Chendu DIAO Pharmaceutical Group CO., LTD. | Overweight and Obesity | 06/25 | 09/25 | | |
NCT04682756: A Multicenter Study on Early Diagnosis of NSTE-ACS Patients Based on Machine Learning Model |
|
|
| Active, not recruiting | N/A | 2500 | RoW | The model of machine learning | First Affiliated Hospital of Xinjiang Medical University, Shihezi University | NSTEMI - Non-ST Segment Elevation MI, Unstable Angina | 12/21 | 06/22 | | |
NCT05540262: Edaravone in the Treatment of Aquaporin-4 Antibody-positive Optic Neuritis |
|
|
| Recruiting | N/A | 18 | RoW | Edaravone | First Affiliated Hospital of Guangxi Medical University | Optic Neuritis | 12/24 | 12/24 | | |
| Chen, Zhendong |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 3 | 663 | RoW | Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel | Shanghai Junshi Bioscience Co., Ltd. | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 05/27 | 05/27 | | |
NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor |
|
|
| Recruiting | 2 | 200 | RoW | TQ-B3101 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumor | 03/21 | 09/21 | | |
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 196 | RoW | TQB2450, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer | 12/21 | 04/22 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 133 | RoW | TJ107 +Pembrolizumab | TJ Biopharma Co., Ltd. | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 06/24 | 12/24 | | |
NCT05068427: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. |
|
|
| Completed | 2 | 34 | RoW | Chidamide, CS055, Envafolimab, KN035 | Chipscreen Biosciences, Ltd. | Non Small Cell Lung Cancer | 02/23 | 05/24 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
|
|
| Withdrawn | 2 | 177 | RoW | Balstilimab, Balstilimab + Zalifrelimab | Agenus Inc., Betta Pharmaceuticals Co., Ltd. | Cervical Cancer | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 222 | RoW | SHR-1701, Famitinib | Jiangsu HengRui Medicine Co., Ltd. | Solid Tumor | 12/22 | 10/23 | | |
NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor |
|
|
| Terminated | 1/2 | 7 | RoW | TJ1133 Injection | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 02/23 | 02/23 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
| Ye, Jun |
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes |
|
|
| Recruiting | 3 | 424 | RoW | Victoza®., Metformin Hydrochloride, TQZ2451 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/21 | 12/21 | | |
| Completed | 3 | 533 | RoW | Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage | Chipscreen Biosciences, Ltd. | Type 2 Diabetes | 02/23 | 02/23 | | |
